{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:33:26Z","timestamp":1783139606359,"version":"3.54.6"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/jtm\/tay018","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T07:58:52Z","timestamp":1519891132000},"source":"Crossref","is-referenced-by-count":33,"title":["Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-0059","authenticated-orcid":false,"given":"Victoria","family":"Hall","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia"},{"name":"Department of General Medicine, Austin Health, Heidelberg, VIC, Australia"},{"name":"Department of Medicine, University of Melbourne, Parkville, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Melbourne, Parkville, VIC, Australia"},{"name":"Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia"},{"name":"Eastern Infectious Diseases and Travel Medicine, Knox Private Hospital, Boronia, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"key\n\t\t\t\t20180925002303_tay018C1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/rheumatology\/ker321","article-title":"Biologic agents for rheumatoid arthritis\u2014negotiating the NICE technology appraisals","volume":"51","author":"Kiely","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180925002303_tay018C3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","article-title":"Infectious complications associated with monoclonal antibodies and related small molecules","volume":"22","author":"Salvana","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180925002303_tay018C5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.idc.2012.06.003","article-title":"The immunosuppressed traveler","volume":"26","author":"Visser","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20180925002303_tay018C6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10158782.2008.11441319","article-title":"The Immunocompromised traveller","volume":"23","author":"Vincent","year":"2008","journal-title":"South Afr Epidemol Infect"},{"key":"key\n\t\t\t\t20180925002303_tay018C7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tmaid.2014.04.009","article-title":"The medically immunocompromised adult traveler and pre-travel counseling: status quo 2014","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"key\n\t\t\t\t20180925002303_tay018C8","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw016","article-title":"Enquiries to the United Kingdom National Travel Advice Line by healthcare professionals regarding immunocompromised travellers","volume":"23","author":"Allen","year":"2016","journal-title":"J Travel Med"},{"issue":"6","key":"key\n\t\t\t\t20180925002303_tay018C9","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taw058","article-title":"Travel vaccination recommendations and endemic infection risks in solid organ transplantation recipients","volume":"23","author":"Trubiano","year":"2016","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.hoc.2010.11.009","article-title":"Infectious complications associated with immunomodulating biologic agents","volume":"25","author":"Koo","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"key\n\t\t\t\t20180925002303_tay018C11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180925002303_tay018C12","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/imj.13371","article-title":"A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia","volume":"47","author":"Wong","year":"2017","journal-title":"Intern Med J"},{"key":"key\n\t\t\t\t20180925002303_tay018C14","first-page":"w14159","article-title":"Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases","volume":"145","author":"Buhler","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"key\n\t\t\t\t20180925002303_tay018C15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/annrheumdis-2013-204427","article-title":"Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)","volume":"74","author":"Bingham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C16","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14760584.2016.1193438","article-title":"Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients","volume":"15","author":"Cheng","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180925002303_tay018C17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tmaid.2014.12.007","article-title":"Travel risk assessment, advice and vaccinations in immunocompromised travellers (HIV, solid organ transplant and haematopoeitic stem cell transplant recipients): a review","volume":"13","author":"Aung","year":"2015","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4269\/ajtmh.15-0185","article-title":"Immunocompromised travelers: demographic characteristics, travel destinations, and pretravel health care from the U.S. Global TravEpiNet Consortium","volume":"93","author":"Schwartz","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180925002303_tay018C19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","article-title":"Tumour necrosis factor inhibitors","volume":"183","author":"Nash","year":"2005","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t20180925002303_tay018C20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4291\/wjgp.v6.i4.219","article-title":"Promising biological therapies for ulcerative colitis: a review of the literature","volume":"6","author":"Akiho","year":"2015","journal-title":"World J Gastrointest Pathophysiol"},{"key":"key\n\t\t\t\t20180925002303_tay018C21","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-12-77","article-title":"Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-\u03b1 antagonists","volume":"12","author":"Germano","year":"2014","journal-title":"J Transl Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/annrheumdis-2014-205246","article-title":"Vaccines and biologics","volume":"73","author":"Ferreira","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C24","volume-title":"The Australian Immunisation Handbook (updated January 2014)","author":"ATAGI","year":"2014","edition":"10th ed"},{"key":"key\n\t\t\t\t20180925002303_tay018C25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","article-title":"Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients","volume":"46","author":"Kapetanovic","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180925002303_tay018C26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2007.077552","article-title":"The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination","volume":"67","author":"Gelinck","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clim.2009.09.014","article-title":"Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity","volume":"134","author":"Salemi","year":"2010","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t20180925002303_tay018C28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial","volume":"22","author":"Debruyn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C30","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/rheumatology\/kes202","article-title":"TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients","volume":"51","author":"Franca","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180925002303_tay018C31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3899\/jrheum.130945","article-title":"Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial","volume":"41","author":"Kivitz","year":"2014","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/lt.22283","article-title":"Immune response to pandemic H1N1 2009 influenza a vaccination in pediatric liver transplant recipients","volume":"17","author":"Haller","year":"2011","journal-title":"Liver Transpl"},{"key":"key\n\t\t\t\t20180925002303_tay018C33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","article-title":"Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis","volume":"45","author":"Kapetanovic","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180925002303_tay018C34","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1002\/art.30580","article-title":"Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors","volume":"63","author":"Kapetanovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C36","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar4127","article-title":"Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C37","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1016\/j.vaccine.2008.04.028","article-title":"Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine","volume":"26","author":"Gelinck","year":"2008","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002303_tay018C38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.vaccine.2014.12.030","article-title":"Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy","volume":"33","author":"Aikawa","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180925002303_tay018C39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jbspin.2015.10.017","article-title":"Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept","volume":"83","author":"Rakoczi","year":"2016","journal-title":"Joint Bone Spine"},{"key":"key\n\t\t\t\t20180925002303_tay018C40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0000000000002184","article-title":"Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate","volume":"94","author":"Migita","year":"2015","journal-title":"Medicine"},{"key":"key\n\t\t\t\t20180925002303_tay018C41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-128-2-199801150-00006","article-title":"Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States","volume":"128","author":"Willner","year":"1998","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","article-title":"Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"12","author":"Askling","year":"2014","journal-title":"Travel Med Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/jtm.12050","article-title":"Seroprotection after hepatitis a vaccination in patients with drug-induced immunosuppression","volume":"20","author":"Van Den Bijllaardt","year":"2013","journal-title":"J Travel Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C44","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/jgh.13001","article-title":"Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients","volume":"30","author":"Andrade","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C45","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.3748\/wjg.v21.i11.3184","article-title":"Updates in vaccination: recommendations for adult inflammatory bowel disease patients","volume":"21","author":"Chaudrey","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t20180925002303_tay018C46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.7326\/M13-2826","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014","volume":"160","author":"Bridges","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.rcreu.2016.02.004","article-title":"Gesti\u00f3n de riesgo para la prescripci\u00f3n de terapias biol\u00f3gicas","volume":"23","author":"Forero","year":"2016","journal-title":"Revista Colombiana de Reumatolog\u00eda"},{"key":"key\n\t\t\t\t20180925002303_tay018C48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3899\/jrheum.091066","article-title":"Abatacept for rheumatoid arthritis: a Cochrane systematic review","volume":"37","author":"Maxwell","year":"2010","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13075-015-0863-3","article-title":"Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients","volume":"17","author":"Migita","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12891-016-1082-z","article-title":"Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept","volume":"17","author":"Alten","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t20180925002303_tay018C51","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","article-title":"Fungal infections and new biologic therapies","volume":"18","author":"Vallabhaneni","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"key\n\t\t\t\t20180925002303_tay018C54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C55","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C56","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"320","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ctrv.2010.11.005","article-title":"Rituximab in Hodgkin lymphoma: is the target always a hit?","volume":"37","author":"Saini","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t20180925002303_tay018C58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20180925002303_tay018C59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"Van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C60","first-page":"1","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C61","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3109\/0284186X.2014.914243","article-title":"The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab","volume":"53","author":"Berglund","year":"2014","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t20180925002303_tay018C62","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/mabs.1.5.9497","article-title":"Tocilizumab","volume":"1","author":"Venkiteshwaran","year":"2009","journal-title":"MAbs"},{"key":"key\n\t\t\t\t20180925002303_tay018C64","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1756-185X.12822","article-title":"Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials","volume":"19","author":"Lee","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C65","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","article-title":"Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis","volume":"71","author":"Mori","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C66","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C67","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/jmbi.1999.2750","article-title":"1.9 A structure of the therapeutic antibody CAMPATH-1 H fab in complex with a synthetic peptide antigen","volume":"289","author":"James","year":"1999","journal-title":"J Mol Biol"},{"key":"key\n\t\t\t\t20180925002303_tay018C68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","article-title":"Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*","volume":"132","author":"Thursky","year":"2006","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180925002303_tay018C69","first-page":"232","article-title":"Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL)","volume":"58","author":"Smolej","year":"2012","journal-title":"Vnitr Lek"},{"key":"key\n\t\t\t\t20180925002303_tay018C70","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes038","article-title":"Immunity 12 years after alemtuzumab in RA: CD5(+) B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses","volume":"51","author":"Anderson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180925002303_tay018C71","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13075-016-1188-6","article-title":"Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies","volume":"18","author":"Cooles","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C72","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"Mccarthy","year":"2013","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20180925002303_tay018C73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40893-016-0011-1","article-title":"Hands on Alemtuzumab-experience from clinical practice: whom and how to treat","volume":"1","author":"Hassoun","year":"2016","journal-title":"Mult Scler Demyelinating Disord"},{"key":"key\n\t\t\t\t20180925002303_tay018C74","author":"Therapeutic Goods Association","year":"2014"},{"key":"key\n\t\t\t\t20180925002303_tay018C75","author":"Davis","year":"2008"},{"key":"key\n\t\t\t\t20180925002303_tay018C76","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C77","author":"U.S. Food and Drug Administration"},{"key":"key\n\t\t\t\t20180925002303_tay018C78","author":"Government of Canada-Health Canada","year":"2016"},{"key":"key\n\t\t\t\t20180925002303_tay018C79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20180925002303_tay018C80","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20180925002303_tay018C81","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key\n\t\t\t\t20180925002303_tay018C82","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm6527a3","article-title":"Notes from the field: meningococcal disease in an international traveler on eculizumab therapy\u2014United States, 2015","volume":"65","author":"Applegate","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180925002303_tay018C83","author":"PNH National Service Leeds and London","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C84","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol"},{"key":"key\n\t\t\t\t20180925002303_tay018C85","author":"Cancer Research United Kingdom","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C86","author":"Cancer Research United Kingdom","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C87","volume-title":"ELCC","author":"Rothschild","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C88","author":"The Pharmaceutical Journal","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C89","author":"British Columbia Cancer Agency","year":"2016"},{"key":"key\n\t\t\t\t20180925002303_tay018C90","author":"Clinicaltrials.Gov","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C91","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"key\n\t\t\t\t20180925002303_tay018C92","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2008.05.033","article-title":"Tuberculosis in the age of biologic therapy","volume":"59","author":"Hernandez","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20180925002303_tay018C94","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20180925002303_tay018C95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.immunol.16.1.27","article-title":"Interleukin-1 receptor antagonist: role in biology","volume":"16","author":"Arend","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"key\n\t\t\t\t20180925002303_tay018C96","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anti-Cancer Drugs"},{"key":"key\n\t\t\t\t20180925002303_tay018C97","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/1471-2334-13-317","article-title":"Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study","volume":"13","author":"Lanini","year":"2013","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C98","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C99","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180925002303_tay018C100","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/BTT.S1828","article-title":"Review of tocilizumab in the treatment of rheumatoid arthritis","volume":"2","author":"Okuda","year":"2008","journal-title":"Biol Targets Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C102","author":"Medsafe","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2863","article-title":"Tocilizumab","volume":"8","author":"Scheinecker","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20180925002303_tay018C104","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"key\n\t\t\t\t20180925002303_tay018C105","author":"Janeway","year":"2001"},{"key":"key\n\t\t\t\t20180925002303_tay018C106","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Ra","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180925002303_tay018C107","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"key\n\t\t\t\t20180925002303_tay018C108","first-page":"504","article-title":"Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma","volume-title":"J Clin Pharm Ther","author":"Tan","year":"2015"},{"key":"key\n\t\t\t\t20180925002303_tay018C109","author":"European Medicines Agency","year":"2015"},{"key":"key\n\t\t\t\t20180925002303_tay018C110","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"key\n\t\t\t\t20180925002303_tay018C111","author":"U.S. Food and Drug Administration","year":"2014"},{"key":"key\n\t\t\t\t20180925002303_tay018C112","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C113","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180925002303_tay018C114","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C115","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","author":"British Thoracic Society Standards of Care, C","year":"2005","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20180925002303_tay018C116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key\n\t\t\t\t20180925002303_tay018C117","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1086\/515402","article-title":"Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis","volume":"44","author":"Geraghty","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C118","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrrheum.2009.105","article-title":"Preventing and treating biologic-associated opportunistic infections","volume":"5","author":"Winthrop","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t20180925002303_tay018C119","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3201\/eid1506.090101","article-title":"Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe","volume":"15","author":"Xynos","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C120","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5694\/mja12.11003","article-title":"Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis","volume":"198","author":"Berry","year":"2013","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t20180925002303_tay018C121","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4269\/ajtmh.2009.81.52","article-title":"Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab","volume":"81","author":"Mueller","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"key\n\t\t\t\t20180925002303_tay018C122","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2013-204011","article-title":"Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy","volume":"74","author":"Yun","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C123","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40360-016-0060-2","article-title":"Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report","volume":"17","author":"Talotta","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20180925002303_tay018C124","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/cid\/cis935","article-title":"Fungal infections in immunocompromised travelers","volume":"56","author":"Lortholary","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C125","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180925002303_tay018C126","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key\n\t\t\t\t20180925002303_tay018C127","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180925002303_tay018C128","author":"Therapeutic Goods Association","year":"2014"},{"key":"key\n\t\t\t\t20180925002303_tay018C129","author":"Government of Canada","year":"2016"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/25\/1\/tay018\/25833953\/tay018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T23:02:26Z","timestamp":1570834946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/tay018\/4934912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":129,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,14]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/tay018","relation":{},"ISSN":["1708-8305"],"issn-type":[{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018]]},"published":{"date-parts":[[2018,1,1]]}}}